Prenetics Global Limited PRE
Regular-session close
After hours · Nov 19, 4:36 PM ET
- YTD
- -34.54%
- 1 year
- -18.88%
5D -7.66 (-42.96%)
- Market cap
- 201.19M
- Revenue (ttm)
- 22.66M
- Profit margin
- -219.78%
- EPS (ttm)
- -3.10
- Shares out
- 10.64M
- Forward P/E
- -10.10
- YTD return
- -34.54%
- 1-year return
- -18.88%
- Volume
- 821.08K
- Avg volume
- 242.23K
- Open
- 10.79
- Previous close
- 10.35
- Day's range
- 9.69 – 11.79
- 52-week range
- 10.31 – 26.25
- Beta
- -0.21
- Price target
- 9.00 (-12.7%)
Key statistics
- 50-day average
- 4.80
- 200-day average
- 5.03
- Enterprise value
- -3.77M
- Price / sales
- 3.05
- Price / book
- 0.33
- Revenue growth
- 4.30%
- Total cash
- 63.89M
- Total debt
- 2.36M
- Return on equity
- -21.67%
- Short % of float
- 0.37%
Fundamental scorecard
8 of 25 checks passed on PRE’s reported financials
8of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 27, 2024 | Sep 1, 2024 | 0.00 | -0.84 | — | — |
| Oct 7, 2024 | Jun 1, 2024 | 0.00 | -0.88 | — | — |
| Oct 7, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jun 18, 2024 | Mar 1, 2024 | 0.00 | -0.38 | — | — |
| Jun 18, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.52 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 4, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Apr 4, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
About Prenetics Global Limited
Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company's consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. Additionally, it is involved in the sports distribution activities providing sports nutrition products to fitness facilities. The company operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- Hong Kong
- Website
- prenetics.com
News
B. Riley Securities Maintains Buy on Prenetics Global, Lowers Price Target to $31
Prenetics (NASDAQ: PRE) raises 2026 revenue guidance and signs Diplo as a shareholder
Prenetics Global Limited (PRE) Q3 2026 Earnings Call Transcript
What Prenetics Global (PRE) Said on Its Q3 Earnings Call
Crude Oil Down Over 4%; Target Earnings Top Views
12 Health Care Stocks Moving In Wednesday's Intraday Session
Dow Falls Over 300 Points; Nvidia Posts Upbeat Earnings Prenetics Global Q3 EPS $(1.43) Misses $(0.72) Estimate, Sales $64.112M Beat $63.188M Estimate
Prenetics Global Affirms FY2026 Sales Guidance of $220.000M-$230.000M vs $224.204M Est
Prenetics' IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+
Your note
Sign in to keep a note on PRE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Prudential PLC | 4.03% | 427,963 | 2.42M | Sep 29, 2024 |
| Aspex Management (HK) Ltd | 3.26% | 346,150 | 1.96M | Sep 29, 2024 |
| Nomura Holdings Inc. | 3.04% | 322,952 | 1.83M | Sep 29, 2024 |
| UBS Group AG | 0.12% | 12,477 | 70.55K | Sep 29, 2024 |
| Morgan Stanley | 0.02% | 2,374 | 13.42K | Sep 29, 2024 |
| Aspire Private Capital, LLC | 0.00% | 114 | 644 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 6,514 | 36.83K | Oct 30, 2024 |
